{Reference Type}: Journal Article
{Title}: Effusanin B Inhibits Lung Cancer by Prompting Apoptosis and Inhibiting Angiogenesis.
{Author}: Hou J;Li Y;Xing H;Cao R;Jin X;Xu J;Guo Y;
{Journal}: Molecules
{Volume}: 28
{Issue}: 23
{Year}: 2023 Nov 21
{Factor}: 4.927
{DOI}: 10.3390/molecules28237682
{Abstract}: Cancer is one of the deadliest human diseases, causing high rates of illness and death. Lung cancer has the highest mortality rate among all malignancies worldwide. Effusanin B, a diterpenoid derived from Isodon serra, showed therapeutic potential in treating non-small-cell lung cancer (NSCLC). Further research on the mechanism indicated that effusanin B inhibited the proliferation and migration of A549 cells both in vivo and in vitro. The in vitro activity assay demonstrated that effusanin B exhibited significant anticancer activity. Effusanin B induced apoptosis, promoted cell cycle arrest, increased the production of reactive oxygen species (ROS), and altered the mitochondrial membrane potential (MMP). Based on mechanistic studies, effusanin B was found to inhibit the proliferation and migration of A549 cells by affecting the signal transducer and activator of transcription 3 (STAT3) and focal adhesion kinase (FAK) pathways. Moreover, effusanin B inhibited tumor growth and spread in a zebrafish xenograft model and demonstrated anti-angiogenic effects in a transgenic zebrafish model.